An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy

Roche

Status: Completed

Conditions: Anemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01716559

ML25362

Details and patient eligibility

About

This observational, prospective, multicenter study will evaluate the treatment response rate and the safety of NeoRecormon (epoetin beta) in anemic patients with non-myeloid malignancy. In addition to NeoRecormon, patients receive chemotherapy for their malignancy. Data will be collected for 16 weeks.

Enrollment: 160 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/=18 years of age
• Presence of solid-tumor or non-myeloid malignancy
• Patients receiving chemotherapy
• Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
• Patients require NeoRecormon

Exclusion criteria

• Hypersensitivity to the drug
• Uncontrolled hypertension
• Female patients if pregnant and/or lactating

Trial design

160 participants in 1 patient group

Cohort